Quantcast

Latest Perrigo Stories

2014-10-23 08:36:06

DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal year 2015 on Thursday, November 6, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO The conference call will be available live via...

2014-10-15 04:22:14

TAINAN, Oct. 15, 2014 /PRNewswire/ -- ScinoPharm (TWSE:1789) announced that it was named the "Active Pharmaceutical Ingredient (API) Supplier of the Year" at the Global Generics and Biosimilars Awards co-hosted by Generics bulletin and Ark Patent Intelligence. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading Pharmaceutical companies including Dr. Reddy's, Teva, Perrigo, Unichem, etc. The...

2014-10-14 12:29:38

OMAHA, Neb., Oct. 14, 2014 /PRNewswire/ -- Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), is proud to announce that its Kansas City, Kansas, manufacturing facility has obtained Safety Quality Food (SQF) Code Edition 7.1, Level 2 Certification. The SQF registration covers the production of all pet treats manufactured in the Kansas-based plant. http://photos.prnewswire.com/prnvar/20141014/151986LOGO SQF is one of several certification bodies recognized by...

2014-10-02 08:30:27

DUBLIN, Oct. 2, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the expiration of its offer to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior Notes due 2016 (the "2016 Exchange Notes"), $600,000,000 of its new 2.30% Senior Notes due 2018 (the "2018 Exchange Notes"), $800,000,000 of its new 4.00% Senior Notes due 2023 (the "2023 Exchange Notes") and...

2014-10-01 08:32:59

DUBLIN, Oct. 1, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the extension of its offer to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior Notes due 2016 (the "2016 Exchange Notes"), $600,000,000 of its new 2.30% Senior Notes due 2018 (the "2018 Exchange Notes"), $800,000,000 of its new 4.00% Senior Notes due 2023 (the "2023 Exchange Notes") and...

2014-09-29 08:30:21

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals. Under the terms of the agreement, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived...

2014-09-29 08:30:04

- AMAG Pharmaceuticals, Inc. to Acquire Lumara Health ST. LOUIS, Sept. 29, 2014 /PRNewswire/ -- Lumara Health(TM) today announced that it has entered into two separate definitive agreements for the sale of its Maternal Health business and separately, the sale of its Women's Healthcare assets. AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) will acquire Lumara Health, Inc. and its wholly owned subsidiaries, including its flagship product, Makena® (hydroxyprogesterone caproate...

2014-09-29 08:30:01

-- Expands Perrigo's Specialty Rx portfolio to include extended topical products in the women's healthcare category DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has signed a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for $82 million in cash. The acquired portfolio generated more than $15...

2014-09-25 16:26:39

TORONTO, Sept. 25, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the year ended June 30, 2014. Selected Highlights Highlights for the Company during the year ended June 30, 2014 and up to the date of this MD&A include the following: ELND005: --...

2014-09-08 12:29:59

Commission Alleges That AbbVie Inc. and Besins Healthcare Inc. Filed Sham Lawsuits; AbbVie and Teva Pharmaceuticals USA, Inc. Entered Anticompetitive Agreement to Delay Generic Entry WASHINGTON, Sept. 8, 2014 /PRNewswire-USNewswire/ -- In its latest action to ensure competition in the nation's healthcare markets, the Federal Trade Commission has filed a complaint in federal district court charging several major pharmaceutical companies with illegally blocking American consumers' access to...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.